Genetic determinants involved in p-aminosalicylic acid resistance in clinical isolates from tuberculosis patients in northern China from 2006 to 2012

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 1320-1324

  Zhang, Xiaobing ^a   Liu, Liguo ^a   Zhang, Yan ^a   Dai, Guangming ^b   Huang, Hairong ^b   Jina, Qi ^a  

^a INSTITUTE OF PATHOGEN BIOLOGY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL GENE; BACTERIUM ISOLATE; BACTERIUM MUTANT; CHINA; FOLC GENE; GENE MUTATION; GENOTYPE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; RIBD GENE; THYA GENE; TUBERCULOSIS; DRUG EFFECTS; GENETICS; MUTATION; MYCOBACTERIUM;

AMINOSALICYLIC ACID; ANTITUBERCULAR AGENTS; CHINA; GENOTYPE; HUMANS; MUTATION; MYCOBACTERIUM; TUBERCULOSIS;

EID: 84921921838     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03695-14     Document Type: Review

References (32)

1. CDC. 2013. WHO publishes global tuberculosis report 2013. Euro Surveill 18:pii =20615. http://www.eurosurveillance.org/ViewArticle.aspx ?ArticleId-20615.
2. Lehmann J. 1946. Para-aminosalicylic acid in the treatment of tuberculosis. Lancet 1:15.
3. Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio MI, Raviglione MC, Rich ML, Royce S, Rüsch-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M. 2011. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 38:516-528. http://dx.doi.org/10.1183/09031936 .00073611.
4. Chakraborty S, Gruber T, Barry CE, III, Boshoff HI, Rhee KY. 2013. Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis. Science 339:88-91. http://dx.doi.org /10.1126/science.1228980.
5. Zhao F, Wang XD, Erber LN, Luo M, Guo AZ, Yang SS, Gu J, Turman BJ, Gao YR, Li DF, Cui ZQ, Zhang ZP, Bi LJ, Baughn AD, Zhang XE, Deng JY. 2014. Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:1479-1487. http: //dx.doi.org/10.1128/AAC.01775-13.
6. Zheng J, Rubin EJ, Bifani P, Mathys V, Lim V, Au M, Jang J, Nam J, Dick T, Walker JR, Pethe K, Camacho LR. 2013. para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. J Biol Chem 288:23447-23456. http://dx.doi.org/10.1074/jbc .M113.475798.
7. Rengarajan J, Sassetti CM, Naroditskaya V, Sloutsky A, Bloom BR, Rubin EJ. 2004. The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria. Mol Microbiol 53:275-282. http://dx.doi.org/10.1111/j.1365-2958.2004.04120.x.
8. Fivian-Hughes AS, Houghton J, Davis EO. 2012. Mycobacterium tuberculosis thymidylate synthase gene thyX is essential and potentially bifunctional, while thyA deletion confers resistance to p-aminosalicylic acid. Microbiology 158:308-318. http://dx.doi.org/10.1099/mic.0.053983-0.
9. Zhang ZD, Zhao YL, Li ZH, Jia HY, Liu YH, Chen X, Liu ZQ, Du BP, Xing AY, Ma Y. 2007. Mutations in the thymidylate synthase gene is a major mechanism in the para-aminosalicylic acid resistance of M. tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi 30:683-685. http://dx.doi.org /10.1016/0956-716x(94)90182-1.
10. Mathys V, Wintjens R, Lefevre P, Bertout J, Singhal A, Kiass M, Kurepina N, Wang XM, Mathema B, Baulard A, Kreiswirth BN, Bifani P. 2009. Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother 53:2100-2109. http://dx.doi.org/10.1128 /AAC.01197-08.
11. World Health Organization Stop TB Department. 2008. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int /hq/2008/WHO-HTM-TB-2008.392-eng.pdf?ua=1.
12. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA, Rist N, Smelev NA. 1969. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 41:21-43.
13. Harmsen D, Dostal S, Roth A, Niemann S, Rothgänger J, Sammeth M, Albert J, Frosch M, Richter E. 2003. RIDOM: comprehensive and public sequence database for identification of Mycobacterium species. BMC Infect Dis 3:26. http://dx.doi.org/10.1186/1471-2334-3-26.
14. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. 1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 35: 907-914.
15. Mathieu M, Debousker G, Vincent S, Viviani F, Bamas-Jacques N, Mikol V. 2005. Escherichia coli FolC structure reveals an unexpected dihydrofolate binding site providing an attractive target for anti-microbial therapy. J Biol Chem 280:18916-18922. http://dx.doi.org/10.1074/jbc .M413799200.
16. Carreras CW, Santi DV. 1995. The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 64:721-762. http://dx.doi.org /10.1146/annurev.bi.64.070195.003445.
17. Kwasigroch JM, Gilis D, Dehouck Y, Rooman M. 2002. PoPMuSiC, rationally designing point mutations in protein structures. Bioinformatics 18:1701-1702. http://dx.doi.org/10.1093/bioinformatics/18.12.1701.
18. Michaels ML, Kim CW, Matthews DA, Miller JH. 1990. Escherichia coli thymidylate synthase: amino acid substitutions by suppression of amber nonsense mutations. Proc Natl Acad Sci U S A 87:3957-3961. http://dx .doi.org/10.1073/pnas.87.10.3957.
19. Li R, Sirawaraporn R, Chitnumsub P, Sirawaraporn W, Wooden J, Athappilly F, Turley S, Hol WG. 2000. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J Mol Biol 295:307-323. http://dx.doi.org /10.1006/jmbi.1999.3328.
20. Bifani PJ, Mathema B, Kurepina NE, Kreiswirth BN. 2002. Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains. Trends Microbiol 10:45-52. http://dx.doi.org/10.1016/S0966-842X(01) 02277-6.
21. Domenech P, Kolly GS, Leon-Solis L, Fallow A, Reed MB. 2010. Massive gene duplication event among clinical isolates of the Mycobacterium tuberculosis W/Beijing family. J Bacteriol 192:4562-4570. http://dx.doi.org /10.1128/JB.00536-10.
22. Ebrahimi-Rad M, Bifani P, Martin C, Kremer K, Samper S, Rauzier J, Kreiswirth B, Blazquez J, Jouan M, van Soolingen D, Gicquel B. 2003. Mutations in putative mutator genes of Mycobacterium tuberculosis strains of the W-Beijing family. Emerg Infect Dis 9:838-845. http://dx.doi.org/10 .3201/eid0907.020803.
23. Köser C.U. , Feuerriegel S., Summers D.K., Archer J.A., Niemann S.. 2012. Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance. Antimicrob Agents Chemother 56:6080-6087. http://dx .doi.org/10.1128/AAC.01641-12.
24. Feuerriegel S, Köser CU, Niemann S. 2014. Phylogenetic polymorphisms in antibiotic resistance genes of the Mycobacterium tuberculosis complex. J Antimicrob Chemother 69:1205-1210. http://dx.doi.org/10.1093/jac /dkt535.
25. Feuerriegel S, Köser C, Trübe L, Archer J, Rüsch Gerdes S, Richter E, Niemann S. 2010. Thr202Ala in thyA is a marker for the Latin American Mediterranean lineage of the Mycobacterium tuberculosis complex rather than para-aminosalicylic acid resistance. Antimicrob Agents Chemother 54:4794-4798. http://dx.doi.org/10.1128/AAC.00738-10.
26. Köser CU, Comas I, Feuerriegel S, Niemann S, Gagneux S, Peacock SJ. 2014. Genetic diversity within Mycobacterium tuberculosis complex impacts on the accuracy of genotypic pyrazinamide drug-susceptibility assay. Tuberculosis (Edinb) 94:451-453. http://dx.doi.org/10.1016/j.tube.2014 .04.002.
27. Eilertson B, Maruri F, Blackman A, Herrera M, Samuels DC, Sterling TR. 2014. High proportion of heteroresistance in gyrA and gyrB in fluo-roquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 58:3270-3275. http://dx.doi.org/10.1128 /AAC.02066-13.
28. Zhang X, Zhao B, Liu L, Zhu Y, Zhao Y, Jin Q. 2012. Subpopulation analysis of heteroresistance to fluoroquinolone in Mycobacterium tuberculosis isolates from Beijing, China. J Clin Microbiol 50:1471-1474. http: //dx.doi.org/10.1128/JCM.05793-11.
29. Zhang X, Zhao B, Huang H, Zhu Y, Peng J, Dai G, Jiang G, Liu L, Zhao Y, Jin Q. 2013. Co-occurrence of amikacin-resistant and -susceptible Mycobacterium tuberculosis isolates in clinical samples from Beijing, China. J Antimicrob Chemother 68:1537-1542. http://dx.doi.org/10.1093 /jac/dkt082.
30. Ängeby K, Juréen P, Kahlmeter G, Hoffner SE, Schön T. 2012. Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. Bull World Health Organ 90:693-698. http://dx .doi.org/10.2471/BLT.11.096644.
31. Simons SO, van Ingen J, van der Laan T, Mulder A, Dekhuijzen PN, Boeree MJ, van Soolingen D. 2012. Validation of pncA gene sequencing in combination with the mycobacterial growth indicator tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol 50:428-434. http://dx.doi.org/10.1128/JCM.05435-11.
32. Simons SO, Mulder A, van Ingen J, Boeree MJ, van Soolingen D. 2013. Role of rpsA gene sequencing in diagnosis of pyrazinamide resistance. J Clin Microbiol 51:382. http://dx.doi.org/10.1128/JCM.02739-12.